Business Description
Affimed NV
NAICS : 541714
SIC : 2833
ISIN : NL0015001ZQ0
Compare
Compare
Traded in other countries / regions
AFMDQ.USA0HL9.UK IPO Date
2018-02-13Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 36.68 | |||||
14-Day RSI | 41.41 | |||||
12-1 Month Momentum % | -99.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Affimed NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.956 | ||
| EPS (TTM) ($) | -4.982 | ||
| Beta | 8.1384 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 1.74 | ||
| Volatility % | 925.95 | ||
| 14-Day RSI | 41.41 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | -99.5 | ||
| 52-Week Range ($) | 0.0001 - 0.02 | ||
| Shares Outstanding (Mil) | 16.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Affimed NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Affimed NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 | In 100 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 100 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 10 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 9 days | ||
| First quarter earnings conference call for 2026 | 2026-08-10 | In 5 days | ||
| First quarter earnings results for 2026 | 2026-08-10 | In 5 days | ||
| General meeting for 2026 | 2026-08-10 | In 5 days | ||
| Guidance call for 2025 | 2025-03-11 14:20 | 0.92 (-7.07%) | ||
| Guidance call for 2024 | 2024-12-17 08:30 | 2.16 (+0.39%) | ||
| Third quarter earnings conference call for 2024 | 2024-11-14 08:30 | 3.72 (-2.20%) |
Show
Entries
Affimed NV Frequently Asked Questions
What is Affimed NV(LTS:0HL9)'s stock price today?
The current price of LTS:0HL9 is $0.00. The 52 week high of LTS:0HL9 is $0.02 and 52 week low is $0.00.
When is next earnings date of Affimed NV(LTS:0HL9)?
The next earnings date of Affimed NV(LTS:0HL9) is 2026-08-10 Est..
Does Affimed NV(LTS:0HL9) pay dividends? If so, how much?
Affimed NV(LTS:0HL9) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Astra Space, PainReform, Vonage, Affimed NV, or Provention Bio? | 2021-11-22 |
Articles on Affimed NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers